August 16, 2024
Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events
Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti
FDA Approves AstraZeneca’s Imfinzi for Use Before and After Lung Cancer Surgery
FDA approval, AstraZeneca, Imfinzi, lung cancer, surgery, neoadjuvant, adjuvant, durvalumab, NSCLC
Biden Administration Announces Historic Lower Drug Prices for Medicare Beneficiaries
Biden Administration, Medicare, Drug Prices, Inflation Reduction Act, Prescription Drug Costs
Neptune Medical Secures $97M in Funding, Launches Jupiter Endovascular Subsidiary
Neptune Medical, Jupiter Endovascular, GI robotics, endovascular technology, Series D financing, medical device innovation, healthcare technology
Incyte Seeks Expanded Approval for Monjuvi Following Successful Phase III Trial in Follicular Lymphoma
Incyte, Monjuvi, follicular lymphoma, Phase III trial, label expansion, tafasitamab, MorphoSys, FDA approval, cancer treatment.
AstraZeneca Wins Patent Infringement Case Against Pfizer, Vacates $107.5M Jury Award
AstraZeneca, Pfizer, patent infringement, jury award, US court
FDA Approval of Amgen’s Imdelltra for Lung Cancer Amidst Challenges and Market Competition
Amgen, Imdelltra, FDA approval, lung cancer, bispecific T-cell engager, adverse events, Merck, Curon, Legend Biotech
England’s NICE Approves Theramex’s Uterine Fibroids Treatment
NICE, Theramex, uterine fibroids, linzagolix, Yselty, GnRH antagonist, hormonal add-back therapy, NHS, women’s health
Boundless Bio Implements Strategic Workforce Reduction to Enhance Operational Efficiency
Boundless Bio, workforce reduction, San Diego, operational efficiency, biotech layoffs